Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 8/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | DPP4 | P27487 | 3/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8100848 | 0.90 | HRH3 (0.44) | CHRM4CYP3A4DPP4HTR1DHRH3 | |
| SCHEMBL13969375 | 0.90 | HTR1D (0.42) | CHRM4CYP3A4DPP4HTR1DHRH3 | |
| SCHEMBL13945453 | 0.89 | CYP3A4 (0.47) | CHRM4CYP3A4DPP4HTR1DOPRM1 | |
| SCHEMBL8094629 | 0.89 | DPP4 (0.47) | CHRM4CYP3A4DPP4HTR1DHRH3 | |
| SCHEMBL4241073 | 0.85 | CHRM4 (0.42) | CHRM4CYP3A4DPP4PDE10A | |
| SCHEMBL13945372 | 0.85 | SMN1; SMN2 (0.52) | CHRM4HTR1D | |
| SCHEMBL8091569 | 0.84 | CYP3A4 (0.49) | CHRM4CYP3A4DPP4TACR1HRH1 | |
| SCHEMBL13945377 | 0.84 | CCR3 (0.47) | CHRM4HTR1DHRH1CCR3KCNH2 | |
| SCHEMBL8088026 | 0.84 | HTR2C (0.40) | CHRM4CYP3A4DPP4 | |
| SCHEMBL8095832 | 0.83 | HRH3 (0.50) | CHRM4HTR1DHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | CHRM4 413/4885CYP3A4 1573/4885DPP4 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.